Skip to main content
GutCited
Figure 4. Relative proportions (percent) of phylum in the fecal samples of treated patients (ZR) and those of placebo (PL) patients.
Figure 11. Figure 4. Relative proportions (percent) of phylum in the fecal samples of treated patients (ZR) and those of placebo (PL) patients.

Descrizione

Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation.

More Figures from This Paper

Alpha diversity indices of fecal microbiota are plotted for treated versus placebo groups, indicating whether probiotic supplementation altered overall bacterial community richness.

Figure 5

Alpha diversity indices of fecal microbiota are plotted for treated versus placebo groups, indicating whether probiotic supplementation altered overall bacterial community richness.

chart
Lactose tolerance test outcomes are compared between intervention groups, with symptom severity mapped against breath hydrogen concentrations.

Figure 6

Lactose tolerance test outcomes are compared between intervention groups, with symptom severity mapped against breath hydrogen concentrations.

chart
A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments.

Figure 7

A CONSORT flow chart traces patient screening and enrollment for this trial of Bifidobacterium longum and Lactobacillus rhamnosus in lactose-intolerant individuals, detailing exclusions for organic diseases and final group assignments.

flowchart
Fecal short-chain fatty acid concentrations are measured across treatment groups, reflecting metabolic activity changes in the gut microbiome following probiotic administration.

Figure 8

Fecal short-chain fatty acid concentrations are measured across treatment groups, reflecting metabolic activity changes in the gut microbiome following probiotic administration.

chart
Individual patient trajectories for bloating severity, measured on a 0-100 mm visual analogue scale, are plotted at baseline and after 30 days for both the probiotic treatment and placebo groups.

Figure 9

Individual patient trajectories for bloating severity, measured on a 0-100 mm visual analogue scale, are plotted at baseline and after 30 days for both the probiotic treatment and placebo groups.

chart
Symptom improvement scores for lactose-intolerant patients receiving a combined Bifidobacterium longum and Lactobacillus rhamnosus preparation are compared with placebo responses over the treatment period.

Figure 10

Symptom improvement scores for lactose-intolerant patients receiving a combined Bifidobacterium longum and Lactobacillus rhamnosus preparation are compared with placebo responses over the treatment period.

chart

Figure 11

Chart
848 × 161px · 43,4 KB

Source Paper

Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota in Patients with Lactose Intolerance and Persisting Functional Gastrointestinal Symptoms: …

Nutrients (2019)

PMID: 31010241

DOI: 10.3390/nu11040886

Cite This Figure

![Figure 11: Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation.](https://pdfs.citedhealth.com/figures/31010241/176.png)

> Source: Paola Vitellio et al. "Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota ." *Nutrients*, 2019. PMID: [31010241](https://pubmed.ncbi.nlm.nih.gov/31010241/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/31010241/176.png" alt="Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation." />
  <figcaption>Figure 11. Relative proportions of bacterial phyla in fecal samples are compared between probiotic-treated and placebo groups, revealing shifts in gut microbiota composition following Bifidobacterium longum and Lactobacillus rhamnosus supplementation.<br>  Source: Paola Vitellio et al. "Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota ." <em>Nutrients</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31010241/">31010241</a></figcaption>
</figure>

Evidenze correlate

A
Lactase per Lactose Intolerance

Grado A · 15 studi

 B
Bifidobacterium longum per Irritable Bowel Syndrome (IBS)

Grado B · 4 studi